These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 24651527)
1. MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma. Asundi J; Lacap JA; Clark S; Nannini M; Roth L; Polakis P Mol Cancer Ther; 2014 Jun; 13(6):1599-610. PubMed ID: 24651527 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma. Schäfer A; Haenig B; Erupathil J; Strickner P; Sabato D; Welford RWD; Klaeylé L; Simon E; Krepler C; Brafford P; Xiao M; Herlyn M; Gstaiger M; Lehembre F; Renz I Oncogene; 2021 Mar; 40(9):1659-1673. PubMed ID: 33500549 [TBL] [Abstract][Full Text] [Related]
3. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330 [TBL] [Abstract][Full Text] [Related]
5. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759 [TBL] [Abstract][Full Text] [Related]
6. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202 [TBL] [Abstract][Full Text] [Related]
7. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
8. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754 [TBL] [Abstract][Full Text] [Related]
9. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299 [TBL] [Abstract][Full Text] [Related]
10. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Wang B; Zhang W; Zhang G; Kwong L; Lu H; Tan J; Sadek N; Xiao M; Zhang J; Labrie M; Randell S; Beroard A; Sugarman E; Rebecca VW; Wei Z; Lu Y; Mills GB; Field J; Villanueva J; Xu X; Herlyn M; Guo W Oncogene; 2021 Sep; 40(37):5590-5599. PubMed ID: 34304249 [TBL] [Abstract][Full Text] [Related]
11. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224 [TBL] [Abstract][Full Text] [Related]
12. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724 [TBL] [Abstract][Full Text] [Related]
13. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Phadke MS; Sini P; Smalley KS Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592 [TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
16. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
17. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors. Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773 [TBL] [Abstract][Full Text] [Related]
18. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471 [TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Carlino MS; Gowrishankar K; Saunders CA; Pupo GM; Snoyman S; Zhang XD; Saw R; Becker TM; Kefford RF; Long GV; Rizos H Mol Cancer Ther; 2013 Jul; 12(7):1332-42. PubMed ID: 23645591 [TBL] [Abstract][Full Text] [Related]
20. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666 [No Abstract] [Full Text] [Related] [Next] [New Search]